This retrospective study provided encouraging CNS ORR, CNS mPFS and other survival data to support that first-line afatinib was also favorable to control BMs in EGFR-positive NSCLC patients, with an acceptable safety profile, even in those with certain uncommon EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.